These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 20842990)

  • 1. Weight loss maintenance.
    Grief SN; Miranda RL
    Am Fam Physician; 2010 Sep; 82(6):630-4. PubMed ID: 20842990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining behavioral and pharmacological treatments for obesity.
    Phelan S; Wadden TA
    Obes Res; 2002 Jun; 10(6):560-74. PubMed ID: 12055334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.
    Elfhag K; Finer N; Rössner S
    Diabetes Obes Metab; 2008 Jun; 10(6):498-505. PubMed ID: 17593239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical options.
    Fujioka K
    Obes Res; 2002 Dec; 10 Suppl 2():116S-123S. PubMed ID: 12490660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weight loss medications--where do they fit in?
    Dixon JB
    Aust Fam Physician; 2006 Aug; 35(8):576-9. PubMed ID: 16894428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
    Mathus-Vliegen EM;
    Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonpharmacologic and pharmacologic management of weight gain.
    Greenberg I; Chan S; Blackburn GL
    J Clin Psychiatry; 1999; 60 Suppl 21():31-6. PubMed ID: 10548140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The new role of pharmacotherapy for weight reduction in obesity.
    Fernstrom MH; Fernstrom JD
    Int J Clin Pract; 2002 Nov; 56(9):683-6. PubMed ID: 12469983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic agents for the treatment of obesity.
    Mathys M
    Clin Geriatr Med; 2005 Nov; 21(4):735-46, vii. PubMed ID: 16182086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term pharmacotherapy for obesity.
    Klein S
    Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medications as adjunct therapy for weight loss: approved and off-label agents in use.
    Moyers SB
    J Am Diet Assoc; 2005 Jun; 105(6):948-59. PubMed ID: 15942547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
    Scheen AJ; Ernest P
    Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment modalities of obesity: what fits whom?
    Hainer V; Toplak H; Mitrakou A
    Diabetes Care; 2008 Feb; 31 Suppl 2():S269-77. PubMed ID: 18227496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients.
    Finer N; Ryan DH; Renz CL; Hewkin AC
    Diabetes Obes Metab; 2006 Mar; 8(2):206-13. PubMed ID: 16448525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
    Rössner S; Sjöström L; Noack R; Meinders AE; Noseda G
    Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical strategies for weight loss in the overweight and obese patient.
    Di Caro S; Hamad GG; Fernstrom MH; Schauer PR; Bonanomi G
    Minerva Gastroenterol Dietol; 2006 Dec; 52(4):415-30. PubMed ID: 17108871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
    Johansson K; Sundström J; Neovius K; Rössner S; Neovius M
    Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weight loss as a treatment for nonalcoholic fatty liver disease.
    Clark JM
    J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S39-43. PubMed ID: 16540766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The treatment of obesity.
    Mina WC; Burns RW; Terry BE
    Mo Med; 2003; 100(3):248-55. PubMed ID: 12847866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.